A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to
investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.